Corticobasal degeneration

key emerging issues

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Corticobasal degeneration (CBD) was first described by Rebeiz et al. in 1967, and was called corticodentatonigral degeneration with neuronal achromasia [1]. Since then, our knowledge of the clinical features and underlying tau pathology has grown tremendously. Clinical antemortem diagnosis of CBD pathology remains challenging and has led to the development of revised diagnostic criteria. As various clinical phenotypes may have CBD pathology, accurate prevalence studies are lacking. Recently, pooled prevalence of fronto-temporal lobar degeneration, PSP and CBS was reported as 10.6 per 100,000 [2]. Although rare, CBD is an important disease to understand because it provides a model of a specific proteinopathy (tauopathy) and, therefore, opportunity to study pathophysiology of tauopathies and efficacy of tau-directed therapies. In the past few years, identification of tau specific ligands has advanced neuroimaging of tauopathies such as CBD and progressive supranuclear palsy. However, clinical prediction of CBD pathology remains challenging and an active are of research. In this review, we highlight key emerging issues in CBD pathophysiology, genetics and novel neuroimaging techniques with tau ligands.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Neurology
DOIs
StateAccepted/In press - Oct 23 2017

Fingerprint

Tauopathies
Pathology
Neuroimaging
Ligands
Progressive Supranuclear Palsy
Cross-Sectional Studies
Phenotype
Research
Therapeutics

Keywords

  • AV-1451
  • Corticobasal degeneration
  • Corticobasal syndrome
  • Tau-PET

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Corticobasal degeneration : key emerging issues. / Ali, Farwa; Josephs, Keith Anthony.

In: Journal of Neurology, 23.10.2017, p. 1-7.

Research output: Contribution to journalArticle

@article{7dde87a53cdc40eaa5442092f36c1be5,
title = "Corticobasal degeneration: key emerging issues",
abstract = "Corticobasal degeneration (CBD) was first described by Rebeiz et al. in 1967, and was called corticodentatonigral degeneration with neuronal achromasia [1]. Since then, our knowledge of the clinical features and underlying tau pathology has grown tremendously. Clinical antemortem diagnosis of CBD pathology remains challenging and has led to the development of revised diagnostic criteria. As various clinical phenotypes may have CBD pathology, accurate prevalence studies are lacking. Recently, pooled prevalence of fronto-temporal lobar degeneration, PSP and CBS was reported as 10.6 per 100,000 [2]. Although rare, CBD is an important disease to understand because it provides a model of a specific proteinopathy (tauopathy) and, therefore, opportunity to study pathophysiology of tauopathies and efficacy of tau-directed therapies. In the past few years, identification of tau specific ligands has advanced neuroimaging of tauopathies such as CBD and progressive supranuclear palsy. However, clinical prediction of CBD pathology remains challenging and an active are of research. In this review, we highlight key emerging issues in CBD pathophysiology, genetics and novel neuroimaging techniques with tau ligands.",
keywords = "AV-1451, Corticobasal degeneration, Corticobasal syndrome, Tau-PET",
author = "Farwa Ali and Josephs, {Keith Anthony}",
year = "2017",
month = "10",
day = "23",
doi = "10.1007/s00415-017-8644-3",
language = "English (US)",
pages = "1--7",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",

}

TY - JOUR

T1 - Corticobasal degeneration

T2 - key emerging issues

AU - Ali, Farwa

AU - Josephs, Keith Anthony

PY - 2017/10/23

Y1 - 2017/10/23

N2 - Corticobasal degeneration (CBD) was first described by Rebeiz et al. in 1967, and was called corticodentatonigral degeneration with neuronal achromasia [1]. Since then, our knowledge of the clinical features and underlying tau pathology has grown tremendously. Clinical antemortem diagnosis of CBD pathology remains challenging and has led to the development of revised diagnostic criteria. As various clinical phenotypes may have CBD pathology, accurate prevalence studies are lacking. Recently, pooled prevalence of fronto-temporal lobar degeneration, PSP and CBS was reported as 10.6 per 100,000 [2]. Although rare, CBD is an important disease to understand because it provides a model of a specific proteinopathy (tauopathy) and, therefore, opportunity to study pathophysiology of tauopathies and efficacy of tau-directed therapies. In the past few years, identification of tau specific ligands has advanced neuroimaging of tauopathies such as CBD and progressive supranuclear palsy. However, clinical prediction of CBD pathology remains challenging and an active are of research. In this review, we highlight key emerging issues in CBD pathophysiology, genetics and novel neuroimaging techniques with tau ligands.

AB - Corticobasal degeneration (CBD) was first described by Rebeiz et al. in 1967, and was called corticodentatonigral degeneration with neuronal achromasia [1]. Since then, our knowledge of the clinical features and underlying tau pathology has grown tremendously. Clinical antemortem diagnosis of CBD pathology remains challenging and has led to the development of revised diagnostic criteria. As various clinical phenotypes may have CBD pathology, accurate prevalence studies are lacking. Recently, pooled prevalence of fronto-temporal lobar degeneration, PSP and CBS was reported as 10.6 per 100,000 [2]. Although rare, CBD is an important disease to understand because it provides a model of a specific proteinopathy (tauopathy) and, therefore, opportunity to study pathophysiology of tauopathies and efficacy of tau-directed therapies. In the past few years, identification of tau specific ligands has advanced neuroimaging of tauopathies such as CBD and progressive supranuclear palsy. However, clinical prediction of CBD pathology remains challenging and an active are of research. In this review, we highlight key emerging issues in CBD pathophysiology, genetics and novel neuroimaging techniques with tau ligands.

KW - AV-1451

KW - Corticobasal degeneration

KW - Corticobasal syndrome

KW - Tau-PET

UR - http://www.scopus.com/inward/record.url?scp=85031939499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031939499&partnerID=8YFLogxK

U2 - 10.1007/s00415-017-8644-3

DO - 10.1007/s00415-017-8644-3

M3 - Article

SP - 1

EP - 7

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -